Calmmax Cream on UP in CKD Patients. Clinical Trial
Uraemic pruritus (UP) remains a frequent and distressing problem in patients with advanced
chronic kidney disease (CKD) and end-stage renal disease (ESRD).
Calmmax is a new topical cream that was introduced recently by Calmmax Pharma, an Israeli
pharmaceutical company developed a topical cream based on active plant extracts for
treatment of skin inflammation. We intend to conduct a prospective, double blind, placebo
controlled, randomized trial that will assess the therapeutic effect of Calmmax cream on UP
in a cohort of CKD and ESRD patients.
n/a
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment